Competing Pharmas Race to Pinpoint Markers Beyond KRAS for Personalized Colorectal Cancer Rx
April 21, 2010
Competing Pharmas Race to Pinpoint Markers Beyond KRAS for Personalized Colorectal Cancer Rx
After missing the first-to-market opportunities with KRAS, both Merck KGaA and Amgen are strategically looking into additional gene markers, with the likely aim of being able to launch companion tests to their drugs that are more sensitive and accurate than the competition.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Merck Serono Survey Finds Limited Test Access, High Costs a Barrier to Personalized Rx Adoption in UK
May 2, 2012 / Pharmacogenomics Reporter - BMS, Amgen's Trials in Wild-Type KRAS Patients Could Clarify PGx Labeling for CRC Drugs
December 7, 2011 / Pharmacogenomics Reporter - Amgen Planning PGx Study to Gain Full Regulatory Approval for Vectibix in US Market
February 9, 2011 / Pharmacogenomics Reporter - With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - Amgen Lays Out Timeline for KRAS Mutation Studies to Dispel Perceptions of Unethical Rx Development
February 24, 2010 / Pharmacogenomics Reporter